Last reviewed · How we verify
ZX-7101A dry suspension
ZX-7101A dry suspension is a Small molecule drug developed by Nanjing Zenshine Pharmaceuticals. It is currently in Phase 1 development.
ZX-7101A dry suspension is being studied for its effects on Respiratory Viral Infection. The pharmacokinetics of ZX-7101A for suspension versus tablets are being evaluated in a clinical study.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ZX-7101A dry suspension |
|---|---|
| Sponsor | Nanjing Zenshine Pharmaceuticals |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza (PHASE3)
- Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With Influenza (PHASE3)
- Study to Evaluate the Pharmacokinetics and Relative Bioavailability of Metabolites in Healthy Chinese Adult Males (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZX-7101A dry suspension CI brief — competitive landscape report
- ZX-7101A dry suspension updates RSS · CI watch RSS
- Nanjing Zenshine Pharmaceuticals portfolio CI
Frequently asked questions about ZX-7101A dry suspension
What is ZX-7101A dry suspension?
Who makes ZX-7101A dry suspension?
What development phase is ZX-7101A dry suspension in?
Related
- Manufacturer: Nanjing Zenshine Pharmaceuticals — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing